You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site


Go Back

International recognition of Synflorix based on rigorous evidence reviews

The use of Synflorix is supported by recommendations of trusted, independent international bodies

“There is at present no evidence of different net impact on overall disease burden between the 2 products [Synflorix and PCV13].

PCV13 may have additional benefit in settings where disease attributable to serotype 19A (ST19A) or serotype 6C (ST6C) is significant.” 12

Current evidence does not indicate an added benefit with one vaccine over the other* 3

“Available evidence to date indicates significant impact of both [Synflorix] and PCV13 in the outcomes studied, with no evidence of the superiority of one vaccine over the other on pneumonia, IPD or meningitis hospitalization reduction in children under 5 years old.” 4


  1. World Health Organization. Guidance for the development of evidence-based vaccination-related recommendations. Version 8; January 31, 2017. Available at: [accessed May 2018].
  2. World Health Organization (WHO). Wkly Epidemiol Rec. 2017;92(48):729-48.
  3. International Vaccine Access Center (IVAC). Pneumococcal conjugate vaccine (PCV) product assessment. April 2017. Available at ivac/resources/pcv-product-assessment-april-25-2017.pdf [accessed May 2018].
  4. de Oliveira LH, et al. PLoS ONE. 2016;11(12):e0166736.

Synflorix is a registered trademark of the GlaxoSmithKline Group of Companies. For the use of Registered Medical Practitioners.

Please report adverse events with any GSK products to the company at